Suchergebnisse - "Kazandjian, Dickran"

PubPharm (95)

61

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Sissung, T. | Peer, C. | Korde, N. | +5

62

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Sissung, T. | Peer, C. | Korde, N. | +5

63

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Sissung, T. | Peer, C. | Korde, N. | +5

64

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2017

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

CommentIn: Leuk Lymphoma. 2017 Mar;58(3):513-515. - PMID 28093000

65

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials

enthalten in: Seminars in oncology | 2017

von Kazandjian, D. | Keegan, P. | Suzman, D. | +2

66

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials

enthalten in: Seminars in oncology | 2017

von Kazandjian, D. | Keegan, P. | Suzman, D. | +2

67

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2017

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

68

Multiple myeloma epidemiology and survival : A unique malignancy

enthalten in: Seminars in oncology | 2016

von Kazandjian, D.

69

A look backward and forward in the regulatory and treatment history of multiple myeloma : Approval of novel-novel agents, new drug development, and longer patient survival

enthalten in: Seminars in oncology | 2016

von Kazandjian, D. | Landgren, O.

70

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Carlsten, M. | Korde, N. | Kotecha, R. | +5